12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Mustang Bio (NASDAQ:MBIO) shares rose 6.9% to $1.39 during Friday's after-market session. The company's market cap stands at $129.8 million.
Mustang Bio Highlights MB-106 CD20-Targeted CAR T Data Selected For Presentations At Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Feb. 3, Feb. 5
Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for
Mustang Bio Q3 EPS $(0.19) Up From $(0.23) YoY
Mustang Bio (NASDAQ:MBIO) reported quarterly losses of $(0.19) per share. This is a 17.39 percent increase over losses of $(0.23) per share from the same period last year.
Mustang Bio Announces Exclusive Worldwide License Agreement With Leiden University Medical Centre For Clinical-Stage Lentiviral Gene Therapy With Curative Potential For RAG1 Severe Combined Immunodeficiency
Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic
3 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy For Treatment Of B-Cell Non-Hodgekin Lymphomas
Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
Mustang Bio Q2 EPS $(0.16) Up From $(0.32) YoY
Mustang Bio (NASDAQ:MBIO) reported quarterly losses of $(0.16) per share. This is a 50 percent increase over losses of $(0.32) per share from the same period last year.